European Journal of Medicinal Chemistry (2020)
Update date:2022-08-03
Topics:
Bukhari, Shazreh
Cabral, Aaron D.
Gawel, Justyna M.
Gunning, Patrick T.
Israelian, Johan
Manaswiyoungkul, Pimyupa
Nawar, Nabanita
Olaoye, Olasunkanmi O.
Radu, Tudor B.
Raouf, Yasir S.
Sedighi, Abootaleb
Shouksmith, Andrew E.
Sina, Diana
Toutah, Krimo
de Araujo, Elvin D.
Dysregulated Histone Deacetylase (HDAC) activity across multiple human pathologies have highlighted this family of epigenetic enzymes as critical druggable targets, amenable to small molecule intervention. While efficacious, current approaches using non-selective HDAC inhibitors (HDACi) have been shown to cause a range of undesirable clinical toxicities. To circumvent this, recent efforts have focused on the design of highly selective HDACi as a novel therapeutic strategy. Beyond roles in regulating transcription, the unique HDAC6 (with two catalytic domains) regulates the deacetylation of α-tubulin; promoting growth factor-controlled cell motility, cell division, and metastatic hallmarks. Recent studies have linked aberrant HDAC6 function in various hematological cancers including acute myeloid leukaemia and multiple myeloma. Herein, we report the discovery, in vitro characterization, and biological evaluation of PTG-0861 (JG-265), a novel HDAC6-selective inhibitor with strong isozyme-selectivity (~36× ) and low nanomolar potency (IC50 = 5.92 nM) against HDAC6. This selectivity profile was rationalized via in silico docking studies and also observed in cellulo through cellular target engagement. Moreover, PTG-0861 achieved relevant potency against several blood cancer cell lines (e.g. MV4-11, MM1S), whilst showing limited cytotoxicity against non-malignant cells (e.g. NHF, HUVEC) and CD-1 mice. In examining compound stability and cellular permeability, PTG-0861 revealed a promising in vitro pharmacokinetic (PK) profile. Altogether, in this study we identified a novel and potent HDAC6-selective inhibitor (~4× more selective than current clinical standards – citarinostat, ricolinostat), which achieves cellular target engagement, efficacy in hematological cancer cells with a promising safety profile and in vitro PK.
View MoreWuxi D-Stone International Co., Ltd.
Contact:+86-510-82740567
Address:21F Hengtong Int'l Centre, 215Zhongshan Road, Wuxi, Jiangsu,China
Contact:86-571-61063068
Address:LINAN
Cerametek Materials(ShenZhen)Co., Ltd.
Contact:+86-755-2324.2554
Address:A3-#9, YongChuan Street, Suite 501
Anhui Biochem United Pharmaceutical Co., Ltd.
Contact:0086 551 5167062 / 5228268
Address:No. 30 Hongfeng Road, Hi-Tech Development Zone, Hefei (230088), China
Jiaozuo Zhongwen Trading Coporation Limited
Contact:+86 0391-3553810
Address:East Renmin Road
Doi:10.1007/s10600-007-0053-x
(2007)Doi:10.1248/yakushi1947.99.5_483
()Doi:10.1016/S0040-4039(01)85828-7
(1978)Doi:10.1080/00397910500212957
(2005)Doi:10.1021/jo0010274
(2000)Doi:10.1002/hlca.19790620447
(1979)